177Lu-Dotatate Ups PFS in Midgut Neuroendocrine Tumors

Share this content:
<sup>177</sup>Lu-Dotatate Ups PFS in Midgut Neuroendocrine Tumors
177Lu-Dotatate Ups PFS in Midgut Neuroendocrine Tumors

THURSDAY, Jan. 12, 2017 (HealthDay News) -- For patients with advanced midgut neuroendocrine tumors, lutetium-177 (177Lu)-Dotatate is associated with longer progression-free survival than high-dose octreotide long-acting repeatable (LAR), according to a study published in the Jan. 12 issue of the New England Journal of Medicine.

Jonathan Strosberg, M.D., from Moffitt Cancer Center in Tampa, Fla., and colleagues randomized 229 patients with well-differentiated, metastatic midgut neuroendocrine tumors to receive 177Lu-Dotatate (116 patients) at a dose of 7.4 GBq every eight weeks plus best supportive care, including octreotide LAR (30 mg administered intramuscularly), or octreotide LAR alone (60 mg administered intramuscularly) every four weeks (113 patients; control group).

The researchers found that the estimated rate of progression-free survival at month 20 was 65.2 and 10.8 percent in the 177Lu-Dotatate and control groups, respectively. The response rate was 18 and 3 percent in the 177Lu-Dotatate and control groups, respectively (P < 0.001). There were 14 and 26 deaths in the 177Lu-Dotatate and control groups, respectively, in the planned interim analysis of overall survival (P = 0.004). One, 2, and 9 percent of patients in the 177Lu-Dotatate group had grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia, respectively, compared with no patients in the control group.

"Treatment with 177Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors," the authors write.

The study was funded by Advanced Accelerator Applications.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Trials Highlight Benefits, Risks of Testosterone Treatment

Trials Highlight Benefits, Risks of Testosterone Treatment

While trials show it boosts bone density and lowers anemia risk, heart risks also seen

Exercise Most Important Lifestyle Change for Breast CA Survivors

Exercise Most Important Lifestyle Change for Breast CA ...

Those who exercised were about 40 percent less likely to die from disease, review suggests

CMS Rule Set to Stabilize Small Health Insurance Markets

CMS Rule Set to Stabilize Small Health Insurance ...

Rule includes special enrollment period pre-enrollment verification, flexibility in level of cover

is free, fast, and customized just for you!

Already a member?

Sign In Now »